GLP-1 Meds Not Linked to Common Thyroid Cancers, Report Finds
The central finding of the white paper is that these medications do not appear to cause or affect the most common forms of thyroid cancer.
This finding addresses patient and provider concerns about the safety of GLP‑1 receptor agonists in relation to the most prevalent thyroid cancer subtypes.
Evidence level: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.
Related signals
- The dual axis of tumorigenesis: MAPK and PI3K/AKT pathways in papillary thyroid carcinoma
- The molecular mechanisms and potential therapeutic implications of the crosstalk between DNA methylation and metabolic reprogramming in thyroid cancer
- Improving predicted risk of recurrence using molecular profiling in papillary thyroid cancer
- Global Burden of Thyroid Cancer in Adults Age 15‑49 Years and Its Predictions: Findings From Global Burden of Disease Study 2021
- Thyroid Cancer: Pathogenesis, Clinicopathology, Diagnosis, and Management